Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Tirabrutinib in Hepatic Impairment
NCT07198087Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Oct 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tirabrutinib in primary central nervous system lymphoma (PCNSL) (4 arms), sponsored by Ono Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration at 72 hours, Time to Maximum Plasma Concentration at 72 hours and 6 more. Started Oct 2025; status: completed.
02
Drugs
tirabrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT07198087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07198087.